Citation 71839

ACHENBACH,H: HUBNER,H: BRANDT,W: REITER,M:. (1994). CARDIOACTIVE STEROID SAPONINS AND OTHER CONSTITUENTS FROM THE AERIAL PARTS OF TRIBULUS CISTOIDES.. 35(6)

Citation Details

TitleCARDIOACTIVE STEROID SAPONINS AND OTHER CONSTITUENTS FROM THE AERIAL PARTS OF TRIBULUS CISTOIDES.
AuthorsACHENBACH,H: HUBNER,H: BRANDT,W: REITER,M:
Year1994
Volume35
Issue6

Summary

Year: 1994

Journal: Unknown

Organisms and Their Experiments (1)

Tribulus cistoides (ZYGOPHYLLACEAE)

Experiment #Pharmacology TypeWorktypesCompoundResults
1Not specified
VOUCHER SPECIMEN REPORTED FORISOLATION AND IDENTIFICATION OFPMR SPECTRUM REPORTEDQUANTITATIVE DATA
TIGOGENIN,NEO:
None
2
SPASMOLYTIC ACTIVITY
PHARMACOLOGY OF EXTRACT - IN VIVO
None
ACTIVE
3Not specified
ISOLATION AND IDENTIFICATION OFMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATA
GITOGENIN,NEO:
None
4Not specified
ISOLATION AND IDENTIFICATION OFPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATA
HECOGENIN,NEO:
None
5Not specified
UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
TYRAMINE,N-DOCOSANOYL:
None
6Not specified
ISOLATION AND IDENTIFICATION OFMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDQUANTITATIVE DATA
TYRAMINE,N-TETRACOSANOYL:
None
7Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
TIGOGENIN,NEO: 3-O-[BETA-XYLOPYRANOSYL(1-2)-[BETA-XYLOPYRANOSYL(1-3))]-BETA-GLUCOPYRANOSYL(1-4)-BETA-GALACTOPYRANOSYL]:
None
8Not specified
ISOLATION AND IDENTIFICATION OFMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDTLC DATA REPORTEDQUANTITATIVE DATA
TRIBULOSIN
None
9
SPASMOLYTIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
TIGOGENIN,NEO: 3-O-[BETA-XYLOPYRANOSYL(1-2)-[BETA-XYLOPYRANOSYL(1-3))]-BETA-GLUCOPYRANOSYL(1-4)-BETA-GALACTOPYRANOSYL]:
INACTIVE
10
SPASMOLYTIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
TRIBULOSIN
WEAK ACTIVITY
11Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDTLC DATA REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
HECOGENIN,NEO: 3-O-[BETA-D-XYLOPYRANOSYL(1-2)-[BETA-D-XYLOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSYL(1-4)-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-BETA-D-GALACTOPYRANOSYL]:
None
12Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDTLC DATA REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
TIGOGENIN,NEO: 3-O-[BETA-D-GLUCOPYRANOSYL(1-2)-[BETA-D-GLUCOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSYL]:
None
13
SPASMOLYTIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
HECOGENIN,NEO: 3-O-[BETA-D-XYLOPYRANOSYL(1-2)-[BETA-D-XYLOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSYL(1-4)-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-BETA-D-GALACTOPYRANOSYL]:TIGOGENIN,NEO: 3-O-[BETA-D-GLUCOPYRANOSYL(1-2)-[BETA-D-GLUCOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSYL]:
ACTIVE
14Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDTLC DATA REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
CISTOCARDIN
None
15Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDTLC DATA REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
TIGOGENIN,NEO: 3-O-[BETA-XYLOPYRANOSYL(1-4)-BETA-GLUCOPYRANOSYL(1-3)-[BETA-GLUCOPYRANOSYL(1-2))]-BETA-GLUCOPYRANOSYL(1-4)-BETA-GALACTOPYRANOSYL):
None
16
SPASMOLYTIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
CISTOCARDIN
ACTIVE
17
SPASMOLYTIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
TIGOGENIN,NEO: 3-O-[BETA-XYLOPYRANOSYL(1-4)-BETA-GLUCOPYRANOSYL(1-3)-[BETA-GLUCOPYRANOSYL(1-2))]-BETA-GLUCOPYRANOSYL(1-4)-BETA-GALACTOPYRANOSYL):
INACTIVE
18Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDTLC DATA REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
HECOGENIN,NEO: 3-O-[BETA-XYLOPYRANOSYL(1-2)-[BETA-GLUCOPYRANOSYL(1-3)]-BETA-GLUCOPYRANOSYL(1-4)-[ALPHA-RHAMNOPYRANSOYL(1-2)]-BETA-GALACTOPYRANOSYL]:
None
19Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
GITOGENIN,NEO: 3-O-[BETA-XYLOPYRANOSYL(1-4)-BETA-GLUCOPYRANOSYL(1-3)-[BETA-GLUCOPYRANOSYL(1-2)]-BETA-GLUCOPYRANOSYL(1-4)-BETA-GALACTOPYRANOSYL]:
None
20
SPASMOLYTIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
HECOGENIN,NEO: 3-O-[BETA-XYLOPYRANOSYL(1-2)-[BETA-GLUCOPYRANOSYL(1-3)]-BETA-GLUCOPYRANOSYL(1-4)-[ALPHA-RHAMNOPYRANSOYL(1-2)]-BETA-GALACTOPYRANOSYL]:
WEAK ACTIVITY
21
SPASMOLYTIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
GITOGENIN,NEO: 3-O-[BETA-XYLOPYRANOSYL(1-4)-BETA-GLUCOPYRANOSYL(1-3)-[BETA-GLUCOPYRANOSYL(1-2)]-BETA-GLUCOPYRANOSYL(1-4)-BETA-GALACTOPYRANOSYL]:
INACTIVE
22Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDTLC DATA REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
FUROSTAN-3-BETA-26-DIOL,5-ALPHA: 3-O-[BETA-D-XYLOPYRANOSYL(1-2)-[BETA-D-XYLOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSYL(1-4)-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-BETA-D-GALACTOPYRANOSYL]-26-(BETA-GLUCOPYRANOSYL)-22-METHOXY: 25(S):
None
23Not specified
ISOLATION AND IDENTIFICATION OFTLC DATA REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATA
PINITOL,D: (+):
None
24Not specified
ISOLATION AND IDENTIFICATION OFTLC DATA REPORTEDQUANTITATIVE DATA
SUCROSE
None
25Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDTLC DATA REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURECD SPECTRUM REPORTED FOR
JASMONIC ACID,5'-(HYDROXY-SULFONYL-OXY):
None
Show SPARQL Queries (1)